Cart (0 Items)
Your cart is currently empty.
View Products-
-
-
InVivoMAb Anti-Human EGFRvIII/EGFR Antibody (3C10)
| Size | 100ug |
|---|---|
| Brand | ProteoGenix |
| Product type | Primary Antibodies |
| Product name | InVivoMAb Anti-Human EGFRvIII/EGFR Antibody (3C10) |
|---|---|
| Buffer | 0.01M PBS, pH 7.4. |
| Delivery condition | Blue ice (+4°C) |
| Delivery lead time in business days | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | Use a manual defrost freezer and avoid repeated freeze thaw cycles.Store at 4°C for frequent use.Store at -20 to -80 °C for twelve months from the date of receipt. |
| Brand | ProteoGenix |
| Host species | Human |
| Aliases /Synonyms | Anti-EGFR, Epidermal growth factor receptor, 2.7.10.1, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, ERBB, ERBB1, HER1 |
| Reference | ARO-A13022 |
| Clonality | Monoclonal Antibody |
| Protein Name | EGFR |
Related products
Primary Antibodies
Human EGFR/ERBB1/HER1 (E7.6.3) Monoclonal Antibody
ARO-A16066 330€
Primary Antibodies
Human EGFR/ERBB1/HER1 Monoclonal Antibody
ARO-A16069 330€
Primary Antibodies
Anti-Human EGFR/ERBB1/HER1 Antibody (11F8), FITC
ARO-A10942 388€
Primary Antibodies
Anti-Human EGFR/ERBB1/HER1 Antibody (E7.6.3), FITC
ARO-A10941 388€
Primary Antibodies
Anti-Human EGFR/ERBB1/HER1 Mouse Antibody (11F8), FITC
ARO-A10940 283€
Primary Antibodies
Anti-Human EGFR/ERBB1/HER1 Human Antibody (11F8), PE
ARO-A10703 505€
Primary Antibodies
Anti-Human EGFR/ERBB1/HER1 Antibody (E7.6.3), PE
ARO-A10702 505€
Primary Antibodies
Anti-Human EGFR/ERBB1/HER1 Antibody (11F8), PE
ARO-A10701 369€
Secondary Antibody
Anti-Human OTUD6A Polyclonal Antibody
ARO-A11121 169€
Secondary Antibody
Anti-Human YEATS2 Polyclonal Antibody
ARO-A11123 169€
Secondary Antibody
Anti-Human ANKRD27 Polyclonal Antibody
ARO-A11126 169€
Secondary Antibody
Anti-Human CDCA7 Polyclonal Antibody
ARO-A11127 169€Contact us
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.